Vestra
Executive Summary
P&U receives second "approvable" letter for the reboxetine antidepressant Feb. 23. P&U said it conducted two U.S. trials for Vestra to supplement the non-U.S. data in its NDA following the first "approvable" letter in July, but only one showed efficacy on the primary endpoint (1"The Pink Sheet" Feb. 14, p. 29)
You may also be interested in...
Pharmacia Vestra
Janssen and Pharmacia terminate co-promotion agreement for anti-depressant Vestra (reboxetine). The norepinephrine reuptake inhibitor has been pending since April 1998, and was been deemed "approvable" in July 1999 and again in February 2000 (1"The Pink Sheet" Feb. 28, In Brief). Pharmacia says an additional Vestra clinical study intended to support approval is nearing completion
Pharmacia Vestra
Janssen and Pharmacia terminate co-promotion agreement for anti-depressant Vestra (reboxetine). The norepinephrine reuptake inhibitor has been pending since April 1998, and was been deemed "approvable" in July 1999 and again in February 2000 (1"The Pink Sheet" Feb. 28, In Brief). Pharmacia says an additional Vestra clinical study intended to support approval is nearing completion
Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says
The sales potential of Pharmacia & Upjohn's overactive bladder treatment Detrol (tolterodine) could be up to half a billion dollars greater than previous projections, pending approval of a once-daily formulation.